DFMO and 5-Azacytidine Increase M1 Macrophages in the Tumor Microenvironment of Murine Ovarian Cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Although ovarian cancer has a low incidence rate, it remains the most deadly gynecologic malignancy. Previous work has demonstrated that the DNMTi 5-Azacytidine (5AZA-C) activates type I interferon signaling to increase IFNγ+ T cells and natural killer (NK) cells and reduce the percentage of macrophages in the tumor microenvironment. To improve the efficacy of epigenetic therapy, we hypothesized that the addition of α-difluoromethylornithine (DFMO), an ornithine decarboxylase inhibitor, may further decrease immunosuppressive cell populations improving outcome. We tested this hypothesis in an immunocompetent mouse model for ovarian cancer and found that in vivo, 5AZA-C and DFMO, either alone or in combination, significantly increased survival, decreased tumor burden, and caused recruitment of activated (IFNγ+) CD4+ T cells, CD8+ T cells, and NK cells. The combination therapy had a striking increase in survival when compared with single-agent treatment, despite a smaller difference in recruited lymphocytes. Instead, combination therapy led to a significant decrease in immunosuppressive cells such as M2 polarized macrophages and an increase in tumor-killing M1 macrophages. In this model, depletion of macrophages with a CSF1R-blocking antibody reduced the efficacy of 5AZA-C + DFMO treatment and resulted in fewer M1 macrophages in the tumor microenvironment. These observations suggest our novel combination therapy modifies macrophage polarization in the tumor microenvironment, recruiting M1 macrophages and prolonging survival. Significance: Combined epigenetic and polyamine-reducing therapy stimulates M1 macrophage polarization in the tumor microenvironment of an ovarian cancer mouse model, resulting in decreased tumor burden and prolonged survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“reconfiguration of the TME (Luo et al., 2018; Travers et al., 2019; Wanget al., 2015; Yu et al., 2019) in support of anticancer immunity or increased sensitivity to CTLA4-or PD-1 blockage”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Travers et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Macrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335 · cited 1×
“MHC II- CD206+ and MHC II+ CD206- macrophages were then sorted via flow 271 cytometry, and RNA was isolated to perform RT-PCR on M1- and M2-specific genes (41-44).”
MethodThe M1 and M2 paradigm of macrophage activation: Time for reassessment
Martinez, F. O., & Gordon, S. (2014) · F1000Prime Reports · doi:10.12703/p6-13 · Cited by 4,689
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652 · cited 1×
“232 Surface PD-1 expression on T cells is a signature of immune tolerance, and when engaged with 233 its ligand PD-L1 on tumor cells, can limit the T cell’s ability to proliferate and perform its 234 effector functions (39,40).”
BackgroundTumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
Transcriptional regulation of macrophage polarization: enabling diversity with identity
Lawrence, T., & Natoli, G. (2011) · Nature Reviews Immunology · doi:10.1038/nri3088 · Cited by 2,284
Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.011 · Cited by 2,022
Self-citationBingle, L., Brown, N. J., & Lewis, C. E. (2002) · The Journal of Pathology · doi:10.1002/path.1027 · Cited by 2,022
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775 · cited 3×
“MHC II- CD206+ and MHC II+ CD206- macrophages were then sorted via flow 271 cytometry, and RNA was isolated to perform RT-PCR on M1- and M2-specific genes (41-44).”
BackgroundMethod
Cited by
Tumor-Associated Macrophages: Recent Insights and Therapies
Zhou, J., Tang, Z., Gao, S., Li, C., Feng, Y., & Zhou, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00188 · Cited by 619
“Significant reduction in M2-polarized macrophages and increased number of tumor-killing M1 macrophages in combination therapy suggest that combination therapy can alter macrophage polarization in the tumor microenvironment, recruit M1 macrophages and prolong survival period (82).”
BackgroundThe emerging role of epigenetic therapeutics in immuno-oncology
Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0266-5 · Cited by 433
Self-citationPolyamines in cancer: integrating organismal metabolism and antitumour immunity
Holbert, C. E., Cullen, M. T., Casero, R. A., & Stewart, T. M. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00473-2 · Cited by 350
Self-citationThe role of tumor-associated macrophages in tumor immune evasion
Huang, R., Kang, T., & Chen, S. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05777-4 · Cited by 230
“…pathology has found that DNMT3B is overexpressed in breast and colorectal cancer (Girault et al. 2003; Nosho et al. 2009), and DNMT inhibitors (DNMTi), such as decitabine and 5-azacytidine (5-AC) can sensitize cancer cells to various therapeutic drugs (Stone et al. 2017; Travers et al. 2019).”
BackgroundImmunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Metadata
- Authors
- Travers, M., Brown, S. M., Dunworth, M., Holbert, C. E., Wiehagen, K. R., Bachman, K. E., Foley, J. R., Stone, M. L., Baylin, S. B., Casero, R. A., & Zahnow, C. A.
- Affiliations
- Johns Hopkins University (US)
- 2Janssen Research & Development, Spring House, Pennsylvania.
- Corresponding author
- Casero, Robert A.
- Zahnow, Cynthia A.
- ORCID
- Venue
- Cancer Research
- Published
- 2019-07-01
- Volume
- 79
- Issue
- 13
- Pages
- 3445-3454
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC6606334
- OpenAlex
- W2945877868
- Cited by
- 103
- References
- 49
- Citations by year
- 2026: 3 · 2025: 22 · 2024: 9 · 2023: 21 · 2022: 16 · 2021: 18 · 2020: 13 · 2019: 1
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI) (CA204345, P30CA006973)
- Samuel Waxman Cancer Research FoundationSamuel Waxman Cancer Research Foundation (SWCRF)
- Crouse-Irving Memorial HospitalCrouse-Irving Memorial Hospital (Crouse-Irving Hospital)
- Dr. Miriam and Sheldon G. Adelson Medical Research FoundationDr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF)
- Janssen PharmaceuticalsJanssen Pharmaceuticals (Janssen Pharmaceuticals, Inc.)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
- Keywords
- ovarian cancer, azacitidine, difluoromethylornithine, M1 macrophages, macrophage polarization, tumor microenvironment, epigenetic therapy, polyamine metabolism, ornithine decarboxylase inhibition, CD4+ T cells, CD8+ T cells, natural killer cells, type I interferon signaling, CSF1R blockade, combination therapy, immunosuppression
- MeSH terms
- Eflornithine, Animals, Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Disease Models, Animal, Female, Immunity, Innate, Macrophages, Mice, Inbred C57BL, Ovarian Neoplasms, Polyamines, Tumor Cells, Cultured, Cystadenocarcinoma, Serous, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: DFMO and 5-Azacytidine Increase M1 Macrophages in the Tumor Microenvironment of Murine Ovarian Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-18-4018
- The paper
- Travers, M., Brown, S. M., Dunworth, M., Holbert, C. E., Wiehagen, K. R., Bachman, K. E., Foley, J. R., Stone, M. L., Baylin, S. B., Casero, R. A., & Zahnow, C. A. (2019). DFMO and 5-Azacytidine Increase M1 Macrophages in the Tumor Microenvironment of Murine Ovarian Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-18-4018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.